Discover the challenges and advantages of outsourcing various pharmaceutical services to multiple providers versus a single service provider. From managing the product lifecycle to ensuring regulatory compliance and communication between teams, find out how a cohesive approach can streamline processes and reduce costs. At Acorn Regulatory, we prioritise your product’s success with our global expertise and commitment to excellence.
Blog
Acorn Regulatory News
Search
Categories
EMA Addresses Stakeholder Queries
The EMA has issued Questions and Answers to Stakeholders on the implications of Regulation (EU) 2023/1182 for centrally authorised medicinal products for human use.
Global DIA Forum for Qualified Persons for PV (Part 1)
We published Part 1 of our report on the Global DIA Forum for Qualified Persons in December 2023. If you missed it, catch up here.
FDA Urges Carbomer Reformulation
The FDA has provided a document attached to support product reformulation for products that contain Carbomer manufactured with Benzene.
MHRA Updated NIMAR Guidance to reflect Windsor Framework
Get up-to-date information about the Northern Ireland MHRA Authorised Route (NIMAR). Check out the recent MHRA Windsor Framework-aligned guidance changes to ensure the legal supply of POMs in the UK and EU. Discover how the Windsor framework will allow ‘PL GB’ packs to be sold in Northern Ireland in January 2025.
Falsified units of Ozempic pens found at wholesaling sites in UK and Europe
Warning: Falsified units of Ozempic pens found at wholesaling sites in UK and Europe, identified while scanning packs as part of FMD checks.
Labelling and packaging of human-use drugs after Windsor Framework agreement
“MHRA updates guidance for UK medicinal product labeling and packaging. Effective January 1, 2025:EU/UK joint packs not allowed in the supply chain.Medicines in the UK (including Northern Ireland) to be authorized separately by MHRA.EU Falsified Medicines Directive no longer applies; ‘UK only’ labeling required.MAHs must submit ‘UK only’ statement by December 31, 2024, with a 6-month over-sticker transition until June 30, 2025. Brought to you by Acorn Regulatory.”
HPRA Guide to labels and leaflets of Human Medicines
Stay Informed with HPRA’s Latest Guidance Updates – AUT-G0035-23 Revision | Medicinal Product Labeling Changes Simplified | Regulatory Compliance Made Easier | Get the Latest Submission Requirements”
Choosing an RMS
Choosing the right Reference Member State (RMS) for your EU procedure can be difficult, Here is some advice to consider, helping you make the choice for your company.
Marketing Authorisation Holder Responsibilities
Acorn Regulatory has worked with a number of MAHs including ‘virtual MAH’s’ to help them understand their responsibilities and develop a QMS suitable for their needs and to support them with each of these responsibilities. MA Holding entities are subject to Market Compliance Inspections by any Health Authority, in any EU country where they hold an MA. The HPRA carry out multiple MAH Market compliance inspections each year.
EU Medical Device Vigilance Reporting: FAQ
We answer some of the most frequently asked questions that we recieve from clients regarding EU Medical Device Vigilance Reporting in this article.
Responsibilities of Importers and Distributors
MDR 2017/745 has greatly expanded the responsibilities of importers and distributors. This article highlights the key responsibilities for both.
EU Medical Device Vigilance Reporting
In this article, we have provided the fundamentals for you to navigate through the EU Medical Device Vigilance Reporting system. Click to read more.
MDR: An Essential Guide for 2021
We have revised our MDR essential guide for 2020 to provide a fresh outlook on the developments of MDR in 2021. Click to read more here.
Conformity Assessment Routes Under MDR 2017/745
This article looks at the increase in requirements under MDR and provides a revised summary on Conformity Assessment Routes. Read more.
Post Market Surveillance under MDR
We provide a new perspective on the specific requirements of Post Market Surveillance (PMS) following the introduction of MDR in 2021. Read more here.
PRRC: Person Responsible for Regulatory Compliance
This revised article concentrates on the role of the Person Responsible for Regulatory Compliance (PRRC). The role of QP is a familiar one for those working in the Pharma sector, but this is the first time in European Medical Devices legislation that a person is...
EUDAMED Registration: Download our slide deck
One of our Senior MDR Regulatory Affairs Consultants, Michelle, provides you with a useful guide to ensure your successful EUDAMED registration. Read more.
What is a Medical Device under MDR 2017/245?
This revised article explores the types of products that may be classified as a medical device in 2021.
How Unique Device Identifiers Work
In this article, we look at the Unique Device Identifiers system under MDR and the requirements it has on all participants of the supply chain. Read more.
Update on the new Veterinary Medicines Regulation (Regulation (EU) 2019/6)
The new veterinary medicines regulation (Regulation (EU) 2019/6) will come into force in January 2022.Get an update on the regulations here.
Acorn Regulatory Secures Manufacturer’s/Importer’s Authorisation Licence
Acorn Regulatory has obtained a Manufacturer’s / Importer’s Authorisation (MIA) licence for Veterinary Use. Find out more here.
Most Read Explainer Articles of 2020
Acorn Regulatory’s website has a wealth of articles that assist regulatory, pharmacovigilance and clinical professionals all over the world. We consistently feature ‘how-to’ and explainer articles. These are the most read ‘how-to’s’ and explainer articles on our website in 2020.
The Northern Ireland Protocol & Medical Devices: Explained
What will be the impact of the Northern Ireland Protocol for medical device companies? We look at the issue in our Northern Ireland Protocol e-book.
How Will The Northern Ireland Protocol Impact Medical Device Companies?
This whitepaper looks at the issues relating to the Northern Ireland Protocol and the medical devices sector and is part of our Brexit series,
How Will The Northern Ireland Protocol Impact Pharma Companies?
How will the Northern Ireland Protocol impact on companies in the pharmaceutical sector? We answer some of the most commonly asked questions.
Do You Need A WDA? Here Is What You Need To Know
If you need a WDA for your company, we can help you to obtain a Wholesale Distribution Authorisation. Contact Acorn Regulatory today.
How to Move from a DCP Close Out To Product Launch
We look at the issue and answer 10 of the most common questions relating to a DCP close-out. Read more here.
Pharmacovigilance KPIs: How They Can Assist You
We have updated this article, one of the most popular on our site. Pharmacovigilance KPIs and how they can assist you. Read the article here.
The Unique Device Identifier system applies new requirements on all participants under MDR. Read the blog and find out more about UDI’s.
Strategy
Subscribe to Our Newsletter
Sign up for our newsletter today and stay informed on the latest regulatory updates and industry insights.






























